Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Secondary loss of response to adalimumab (ADA‐LOR) commonly occurs in patients with Crohn's disease (CD) treated with adalimumab (ADA). We evaluated the efficacy of concomitant elemental diet (ED) therapy to reduce ADA‐LOR in adult CD patients.

[1]  Z. Zeng,et al.  Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease , 2017, Journal of Gastroenterology.

[2]  T. Matsui,et al.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.

[3]  R. Baldassano,et al.  Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease , 2016, Inflammatory bowel diseases.

[4]  T. Matsui,et al.  Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease , 2016, Journal of Crohn's & colitis.

[5]  S. Vermeire,et al.  Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial , 2015, Gut.

[6]  M. Barreiro-de Acosta,et al.  Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice , 2015, European journal of gastroenterology & hepatology.

[7]  A. Tsertsvadze,et al.  Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. , 2015, Health technology assessment.

[8]  P. Rutgeerts,et al.  Factors associated with short- and long-term outcomes of therapy for Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  J. Barkin,et al.  The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study , 2015, Gut.

[10]  K. Tominaga,et al.  Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response , 2015, Digestive Diseases and Sciences.

[11]  L. Dieleman,et al.  Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[12]  Merel E Hellemons,et al.  Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients. , 2014, Journal of Crohn's & colitis.

[13]  G. Macedo,et al.  Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience. , 2014, Journal of Crohn's & colitis.

[14]  T. Matsui,et al.  C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease , 2014, Journal of Gastroenterology.

[15]  M. Nakahigashi,et al.  Enteral nutrition to suppress postoperative Crohn’s disease recurrence: a five-year prospective cohort study , 2013, International Journal of Colorectal Disease.

[16]  T. Matsui,et al.  Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan , 2012, Journal of Gastroenterology.

[17]  T. Matsui,et al.  Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn’s Disease in Adults , 2012, Digestive Diseases and Sciences.

[18]  T. Matsui,et al.  Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease , 2012, Inflammatory bowel diseases.

[19]  T. Hibi,et al.  Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. , 2012, Journal of Crohn's & colitis.

[20]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[21]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[22]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[23]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[24]  T. Ikizler,et al.  Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[25]  G. Haroske,et al.  Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata , 2008 .

[26]  G. Haroske,et al.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. , 2008, American journal of clinical dermatology.

[27]  M. Nakahigashi,et al.  Impacts of long‐term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: A prospective study , 2007, Inflammatory bowel diseases.

[28]  T. Yamamoto,et al.  Impact of long‐term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: a prospective, non‐randomized, parallel, controlled study , 2006, Alimentary pharmacology & therapeutics.

[29]  S. Kuriyama,et al.  Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized‐controlled trial , 2006, Alimentary pharmacology & therapeutics.

[30]  Tomomi Kimura,et al.  Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease , 2006, Journal of gastroenterology and hepatology.

[31]  P. Gionchetti,et al.  The management of refractory Crohn's disease , 2002 .

[32]  P. Gionchetti,et al.  Review article: the management of refractory Crohn's disease. , 2002, Alimentary pharmacology & therapeutics.

[33]  T. Matsui,et al.  Crohn’s Disease in Japan: Diagnostic Criteria and Epidemiology , 2000 .

[34]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[35]  J. Hampe,et al.  Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. , 1999, Lancet.

[36]  T. Toyota,et al.  Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease , 1998, Gut.